2014

Global Human Growth Hormone Drugs Industry

NEW YORK, Oct. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Human Growth Hormone Drugs Industry

http://www.reportlinker.com/p01010194/Global-Human-Growth-Hormone-Drugs-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 37 companies including many key and niche players such as Eli Lilly and Company, Ferring Pharmaceuticals A/S, Genentech, Inc., GeneScience Pharmaceuticals Co., Ltd., Merck Serono SA, Sandoz International GmbH, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceutical Industries Limited. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Analytics in the report refer to sales of prescription

therapeutic growth hormone drugs I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Market Primer II-1

Analysis by Geographic Region II-1

US - The Single Largest Market for HGH Drugs II-1

Europe - High Potential Market for HGH Drugs II-2

Prescription Variants - Higher in Efficacy and Prices II-2

List of Select Approved Prescription hGH Products by Indication II-2

Key Market Drivers II-3

Major Market Restraining Factors II-3

2. TRENDS & ISSUES II-4

Recombinant hGH Propels Regulatory Approvals II-4

Non-Growth Hormone Deficiency Uses - Well Explored II-4

Adult Growth Hormone Deficient Market - Largely Under Penetrated II-4

Limited Pharmacological Differences Exist Among Current Agents II-4

Long-Acting hGHs - the Flavor of the Season II-5

Sustained-Release hGH Products in Pipeline II-5

Risk of Cancer Necessitates Judicious Use of hGH in Children II-5

Other Concerns for Growth Hormone Use II-6

Biosimilars Create Little Impact, Further Validation to Expand

Indications and Growth II-6

Biosimilar hGH First Product Launch in Select Countries

Worldwide II-6

Biobetters Restrict Biosimilars' Presence in Prescription hGH

Market II-7

Phase IV Studies Necessitated for First Biosimilars II-7

Novel Drug Delivery Methods Come to Originators' Rescue II-7

Next Generation hGH Products Promise Superior Adoption II-7

Dose Titration - A Key to Achieve Enhanced Tolerability II-8

Delivery Device Dynamics II-8

Delivery Device Options for Marketed hGH Products II-9

3. COMPETITION II-10

Multiple Manufacturers of hGH - Intensify Market Competition II-10

Table 1: Leading Companies in the Global Human Growth Hormone

Drugs Market (2011): Percentage Breakdown of Dollar Sales for

Novo Nordisk, Pfizer, Roche, Eli Lilly and Company and Others

(includes corresponding Graph/Chart) II-10

Manufacturers Bet on Novel Drug Delivery Technologies II-10

Saizen's Patronage Grows, Revenues Sulk II-11

Technological Advancements Continue II-11

Merck-Serono Continues Studying Saizen II-11

Norditropin' Sales Continues to Flourish II-11

New Delivery Device Eases Administration II-11

Genotropin's Sales Stagnate II-12

Omnitrope - the Somatropin Biosimilar II-12

4. HUMAN GROWTH HORMONE: AN OVERVIEW II-13

Human Growth Hormone: An Introduction II-13

History II-13

Key Factors Controlling Natural hGH Secretion II-13

Structure of hGH II-14

Functions Performed by hGH in the Human Body II-14

Benefits of Adequate hGH II-15

Effects of Human Growth Hormone Imbalances II-15

Dangers of Excessive Intake of hGH II-16

Causes of Hypopituitarism II-16

Requirement of Synthetic Human Growth Hormone II-16

Types II-17

Somatotropin/Cadaver-GH II-17

Somatrem/Inclusion Body Technology/Met-hGH II-17

Somatropin/Mouse-Cell Manufacturing and Protein Secretion

Technology/rhGH II-17

Benefits of Synthetic hGH Replacement Therapy II-17

Symptoms, Diagnosis and Treatment of hGH Deficiency in

Children and Adults II-18

In Children II-18

Symptoms II-18

Diagnostic Procedures II-18

Key Procedure for Pediatric hGH Deficiency Treatment II-19

In Adults II-20

Symptoms II-20

Diagnostic Procedures II-20

Treatment Options for AGHD II-21

HGH Therapy II-21

Types of hGH Therapy II-21

Human Growth Hormone Injection Therapy II-21

Human Growth Hormone Secretagogues Therapy II-21

Human Growth Hormone Releaser Therapy II-22

Types of hGH Products II-22

Human Growth Hormone Injections II-22

Human Growth Hormone Homeopathic Formulas II-22

Human Growth Hormone Supplements (Pills/Capsules) II-22

Insulin-like Growth Factor-1 II-23

Leading hGH Pills II-23

hGH Releasers II-24

hGH Releaser Stimulators II-24

Effects of hGH Releasers II-24

Safety and hGH Therapy II-25

In Children II-25

In Adults II-26

5. RECENT INDUSTRY ACTIVITY II-27

hGHmeds.com Unveils Xerendip Human Growth Hormone II-27

PROLOR Biotech Commences Phase 2 Trials of hGH-CTP II-27

Merck Serono Begins Clinical Study of Easypod Electronic Auto -

Injector II-28

Sandoz Introduces Somatropin Growth Hormone in Japan II-28

Dainippon Sumitomo Pharma Inks Agreement with JCR

Pharmaceuticals for Growth Hormone Business II-28

Pfizer Establishes Biotech Unit in Sweden II-28

Modigene Commences Operations as PROLOR Biotech II-29

Sandoz's Omnitrope® Obtains FDA Approval for New Indication II-29

Novo Nordisk's Norditropin® FlexPro® Injection Pen Obtains US

FDA Approval II-29

Prolor's hGH-CTP Obtains Orphan Drug Status II-29

Ascendis Pharma Starts Phase 2 Clinical Trial of ACP-001 II-29

Teva and Antares Receive FDA Approval for hGH Needle-Free

Injection II-30

Eli Lilly Receives FDA Approval for Humatrope Injection II-31

Pharmacia and Upjohn Receive FDA Approval for Genotropin

Injection II-31

Prolor Biotech Received Two US Patents for Longer-Acting EPO

and Longer-Acting hGH II-31

Ranbaxy Laboratories to Develop Novel Growth Hormone II-31

6. FOCUS ON SELECT GLOBAL PLAYERS II-32

Eli Lilly and Company (US) II-32

Ferring Pharmaceuticals A/S (Switzerland) II-32

Genentech, Inc. (US) II-32

GeneScience Pharmaceuticals Co., Ltd. (China) II-33

Merck Serono SA (Switzerland) II-33

Sandoz International GmbH (Germany) II-33

Novo Nordisk A/S (Denmark) II-34

Pfizer, Inc. (US) II-34

Teva Pharmaceutical Industries Limited (Israel) II-35

7. GLOBAL MARKET PERSPECTIVE II-36

Table 2: World Recent Past, Current and Future Analysis for

Human Growth Hormone Drugs by Geographic Region - US, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2018 (includes corresponding Graph/Chart) II-36

Table 3: World 10-Year Perspective for Human Growth Hormone

Drugs by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2009, 2012, and 2018 (includes corresponding

Graph/Chart) II-37

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current & Future Analysis III-1

FDA Approvals Clears Way for Treating More Children III-1

Major hGH Products and FDA Approved Indications III-1

FDA Approval of First Biosimilars III-2

FDA Regulations Governing Human Growth Hormone Products in

OTC Drugs Market III-2

Strategic Corporate Developments III-3

Select Key Players III-6

B.Market Analytics III-8

Table 4: US Recent Past, Current and Future Analysis for

Human Growth Hormone Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2018 (includes

corresponding Graph/Chart) III-8

2. JAPAN III-9

A.Market Analysis III-9

Current & Future Analysis III-9

Sandoz' Omnitrope - the First Biosimilar hGH Launched in Japan III-9

Regulatory Environment in Japan III-9

Strategic Corporate Developments III-9

B.Market Analytics III-10

Table 5: Japanese Recent Past, Current and Future Analysis

for Human Growth Hormone Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2018 (includes

corresponding Graph/Chart) III-10

3. EUROPE III-11

A.Market Analysis III-11

Current & Future Analysis III-11

A Focus on Regulations Pertaining to Biosimilars in the EU III-11

Uneven Adoption of Biosimilar hGH across EU Members III-11

Table 6: Biosimilar hGH Share of Originator Drug Sales in

the EU by Country: 2011 (includes corresponding

Graph/Chart) III-11

New Indications to Drive Future Growth III-12

Strategic Corporate Developments III-12

Select Key Players III-13

B.Market Analytics III-16

Table 7: European Recent Past, Current and Future Analysis

for Human Growth Hormone Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2018 (includes

corresponding Graph/Chart) III-16

4. REST OF WORLD III-17

A.Market Analysis III-17

Current & Future Analysis III-17

Strategic Corporate Development III-17

GeneScience Pharmaceuticals Co., Ltd. - A Key Chinese

Producer of hGH III-17

B.Market Analytics III-18

Table 8: Rest of World Recent Past, Current and Future

Analysis for Human Growth Hormone Drugs Analyzed with Annual

Sales Figures in US$ Million for Years 2009 through 2018

(includes corresponding Graph/Chart) III-18

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 37 (including Divisions/Subsidiaries - 41)

The United States (14)

Canada (1)

Japan (1)

Europe (11)

- France (1)

- Germany (2)

- The United Kingdom (1)

- Rest of Europe (7)

Asia-Pacific (Excluding Japan) (10)

Latin America (1)

Middle-East (3)

To order this report:

Biopharmaceutical Industry: Global Human Growth Hormone Drugs Industry

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.